Skip to Main Content

Paper Details

UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Br J Ophthalmol
30
2017
AMD, Aflibercept, Diabetic Retinopathy, aflibercept, nAMD, neovascular age-related macular degeneration, patients, ranibizumab
Aged, Angiogenesis Inhibitors, Cost-Benefit Analysis, Electronic Health Records, Female, Humans, Intravitreal Injections, Male, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Treatment Outcome, United Kingdom, Visual Acuity, Wet Macular Degeneration
Author NameAffiliation
Aaron LeeUniversity of Washington
Aaron LeeMoorfields Eye Hospital NHS Foundation Trust
Cecilia S LeeUniversity of Washington
Catherine EganUCL Institute of Ophthalmology
Catherine EganThe NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation TrustLondonUK
Clare BaileyBristol Eye Hospital
Robert L JohnstonGloucestershire Hospitals NHS Foundation Trust
Salim NathaWigan and Leigh NHS Foundation Trust
Robin HamiltonUCL Institute of Ophthalmology
Rehna KhanCalderdale and Huddersfield NHS Foundation Trust
Sahar Al-HusainyHeart of England NHS Foundation Trust
Christopher BrandSheffield Teaching Hospitals NHS Foundation Trust
Toks AkereleHinchingbrooke Health Care NHS Trust
Martin McKibbinLeeds Teaching Hospitals NHS Trust
Louise DowneyHull and East Yorkshire Hospitals NHS Foundation Trust
Adnan TufailUCL Institute of Ophthalmology
Adnan TufailThe NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation TrustLondonUK
  • 1 - 17

Datasets

Release 1.2